- Home
- HRTX vs KPTI Comparison
HRTX vs KPTI Comparison
Compare HRTX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | KPTI |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.3M | 194.8M |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HRTX | KPTI |
|---|---|---|
| Price | $0.87 | $8.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 2.3M | 420.1K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $146,067,000.00 |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | 0.57 |
| 52 Week Low | $0.74 | $3.65 |
| 52 Week High | $2.30 | $10.99 |
Technical Indicators
Market Signals| Indicator | HRTX | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 57.55 |
| Support Level | $0.74 | $5.43 |
| Resistance Level | $0.87 | $9.32 |
| Average True Range (ATR) | 0.07 | 0.75 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 7.88 | 63.32 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).